Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

85
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
85
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zanidatamab: First Approval.

Drugs·2025
Same author

Macitentan: Pediatric First Approval.

Paediatric drugs·2025
Same author

Flurpiridaz F 18: First Approval.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2025
Same author

Arimoclomol: First Approval.

Drugs·2024
Same author

Axatilimab: First Approval.

Drugs·2024
Same author

Vunakizumab: First Approval.

Drugs·2024
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Nov 22, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.5K

Lumasiran: First Approval.

Lesley J Scott1, Susan J Keam2

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|January 6, 2021
PubMed
Summary
This summary is machine-generated.

Lumasiran, a novel RNAi therapeutic, effectively reduces oxalate synthesis for primary hyperoxaluria type 1 (PH1) treatment. This groundbreaking therapy has received regulatory approval in the EU and USA for all PH1 patients.

More Related Videos

Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
05:56

Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases

Published on: January 9, 2019

8.1K
Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
11:09

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

Published on: July 13, 2010

40.0K

Related Experiment Videos

Last Updated: Nov 22, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.5K
Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
05:56

Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases

Published on: January 9, 2019

8.1K
Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
11:09

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

Published on: July 13, 2010

40.0K

Area of Science:

  • Pharmacology
  • Genetics
  • Biochemistry

Background:

  • Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder characterized by excessive oxalate production.
  • Oxalate accumulation leads to severe kidney damage and systemic complications.
  • Current treatment options for PH1 are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To summarize the key development milestones of lumasiran, a small interfering RNA (siRNA) therapy.
  • To detail the regulatory approvals of lumasiran for the treatment of PH1.
  • To provide an overview of lumasiran's mechanism of action in managing PH1.

Main Methods:

  • Lumasiran is a subcutaneously administered siRNA targeting the hydroxyacid oxidase 1 gene (HAO1).
  • It silences the gene encoding glycolate oxidase, thereby inhibiting oxalate synthesis.
  • The development pathway involved preclinical studies, clinical trials, and regulatory submissions.

Main Results:

  • Lumasiran demonstrated successful inhibition of glycolate oxidase and reduction in oxalate synthesis.
  • The therapy received its first global approval in the EU on November 19, 2020, for all age groups.
  • US FDA approval followed on November 23, 2020, for adult and pediatric patients.

Conclusions:

  • Lumasiran represents a significant advancement in PH1 treatment.
  • Its targeted mechanism offers a new therapeutic approach for patients with PH1.
  • The drug's approval marks a major milestone in addressing the unmet medical needs of PH1 patients.